Take care and strategic milestones

• Revenue: Approx. 250,000 $ 44% compared to the first quarter of 2024.

• Operating costs: Dropped 35% compared to the second quarter of 2024.

• Net money used for operating activities: 4.3 million US dollars, compared to 8.3 million US dollars in the first quarter of 2024.

• Cash and cash equivalent: 2.6 million US dollars at the end of the first quarter of 2025, compared to 3.3 million US dollars at the end of 2024.

• Non -dilutive financing: Credit financing of USD 1.6 million and scholarships of $ 0.2 million.

• Cabrio -loan note: Gross revenues of 6.25 million US dollars that are repaid over 24 months.

• First income from the sales of the human product: Reached in Q1 2025.

• Nu.Q NETS product sale: First income from CE-marked product in Europe.

• Nu.q Vet milestone payments: 23 million US dollars that have been received in addition to the ongoing income.

Appearance date: May 16, 2025

You can find the complete copy of the earnings call in the complete earnings call.

• Volitionrx LTD (VNRX) achieved a sales increase by 44% compared to the first quarter of 2024 and was significant growth.

• The operating costs were reduced by 35% compared to the previous year, which shows effective cost management.

• The company achieved its first income from the sale of human products, an important milestone in its commercialization efforts.

• Volitionrx LTD is in confidential discussions with over 10 companies for license agreements and shows a strong interest in his technology.

• The company has not secured dilutive funds, including grants and loans, which supports its financial stability.

• In this early phase of commercialization, the income remains unpredictable and “clumpy”, which makes the financial forecast difficult.

• Cash and cash equivalents decreased from $ 3.3 million to USD $ 2.6 million at the end of 2024, which indicates careful cash management.

• The company does not offer any income instructions for 2025, which may create uncertainty for investors.

• Volitionrx LTD is competing with the competition of larger companies that can burn hundreds of million annually.

• The commercialization of new products such as the cat cancer test is still in progress and can take time to achieve significant income.

Q: The operating costs remained low in this quarter. Is this a sustainable level for WaffenRX to maintain throughout 2025? A: Cameron Reynolds, President, CEO, director: It is of crucial importance for us to effectively manage the costs, especially if we concentrate on commercialization. We want to keep the costs low by using partnerships in which large players process laboratory work and regulatory studies. Terig Hughes, CFO: We strive to maintain close cost control in all categories, and this focus will continue all year round.